ArticlePloS one2025
AgNPs treatment reduces time recovery and increases bacterial sensitivity to antibiotics in cow´s purulent catarrhal endometritis. A translational study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cow purulent catarrhal endometritis (PCE) is a common reproductive disorder in dairy cattle caused by bacterial infections. PCE impacts fertility, milk production, and animal health. Therapeutic approaches include systemic or intrauterine antibiotics. Unfortunately, the overuse of antibiotics in treating PCE drives the emergence of antibiotic-resistant bacteria, making infections difficult to treat and increasing food safety concerns due to antibiotic residues remaining in milk and meat products, posing health risks to consumers. Antimicrobial nanomaterials, particularly silver nanoparticles (AgNPs), provide an efficient alternative to combat multi-resistant bacteria, and the synergistic activity of AgNPs and antibiotics has been well documented, making the treatments of bacterial infections more efficient. Here, a comparative study is shown applying Argovit-C (AgNPs) and Enrocide as therapeutics for treating PCE in cattle. Intrauterine application of Argovit-C reduces the recovery time of cattle in comparison with Enrocide treatment as well as increases the sensitivity to antibiotics of Escherichia coli isolates from cervical canal secretion samples of diseased cattle. The increased sensitivity was found to 24 antibiotics, including aminoglycosides, fluoroquinolones, tetracyclines, penicillins, cephalosporins, macrolides, polymyxin, rifampicin, and chloramphenicol. The increased sensitivity was much higher for those bacteria that did not show an active efflux effect. Furthermore, Argovit-C reduced the acquisition of blaDHA and blaGES resistance genes in E. coli, as well as the number of bacterial isolates without efflux effect. Overall, this translational study performed in 300 cows demonstrates the ability of Argovit-C AgNPs to combat bacterial infections, favoring an increase in bacterial susceptibility to antibiotics and reducing their ability to acquire antibiotic multi-resistant genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.